Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
J Immunother Cancer
; 9(3)2021 03.
Article
in En
| MEDLINE
| ID: mdl-33785610
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Skin Neoplasms
/
Biological Products
/
Lymphocytes, Tumor-Infiltrating
/
Herpesvirus 1, Human
/
CD8-Positive T-Lymphocytes
/
Oncolytic Viruses
/
Oncolytic Virotherapy
/
Tumor Microenvironment
/
Melanoma
Type of study:
Clinical_trials
/
Diagnostic_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
J Immunother Cancer
Year:
2021
Type:
Article
Affiliation country:
Spain